Collecting Tumor Samples From Patients With Gynecological Tumors - Full Text View

Sponsor:	Gynecologic Oncology Group
Collaborator:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00897442

Purpose

RATIONALE: Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.

PURPOSE: This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors.

Condition	Intervention
Cancer	Other: biologic sample preservation procedure

Study Type:	Observational
Official Title:	Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Cervical Cancer Vaginal Cancer Vulvar Cancer

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Collection of gynecological tumor specimens and serum from patients at GOG institutions [ Designated as safety issue: No ]
Create a repository for long-term storage of these specimens [ Designated as safety issue: No ]

Study Start Date:

June 1992

Detailed Description:

OBJECTIVES:

Collect gynecological tumor specimens and blood from patients at GOG institutions.
Provide a repository for long-term storage of these specimens.

OUTLINE: Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.

PROJECTED ACCRUAL: Not specified

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Any of the following:
- Patients who have had gynecologic tissue removed during surgery to diagnosis, treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, meeting at least one of the following criteria:
  - Group A: Women who underwent surgery, were diagnosed with a primary gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and have primary tumor, normal tissue, and blood available for submission for this protocol
    - Patients with ovarian cancer including all stages, grades, and common epithelial cell types
      - Invasive cancers and serous and mucinous borderline tumors of low malignant potential are allowed
      - At least 1 gram of frozen primary tumor tissue must be submitted for this protocol for patients with FIGO stage III or IV epithelial ovarian cancer
    - Patients with an invasive malignancy of the cervix or uterine corpus including all stages, grades, and common cell types
    - Patients with squamous cell carcinoma of the vulva
  - Group B: Women who underwent surgery and were diagnosed with a rare gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor arising in endometriosis, and have tumor tissue available for submission for this protocol
    - Patients with a rare gynecologic malignancy of the ovary including malignant germ cell tumors; sex cord-stromal tumors; malignant mixed mesodermal tumors; clear cell, mucinous, small cell, or transitional cell carcinomas; malignant Brenner tumors; or borderline tumors of low malignant potential (except serous and mucinous)
    - Patients with a rare gynecologic malignancy of the peritoneum, including primary peritoneal cancer or mesothelioma
    - Patients with carcinoma of the fallopian tube
    - Patients with a rare gynecologic malignancy of the cervix including verrucous, small cell, clear cell, serous, or adenoid cystic carcinomas; carcinoid tumors; malignant mixed mesodermal tumors; or leiomyosarcoma
    - Patients with a rare gynecologic malignancy of the uterine corpus including leiomyosarcoma; malignant mixed mesodermal tumors; endometrial stromal sarcomas; smooth muscle tumors of unknown malignant potential; or clear cell or small cell carcinomas
    - Patients with a rare gynecologic malignancy of the vagina including verrucous or clear cell carcinomas; melanoma; embryonal rhabdomyosarcoma; or endodermal sinus tumor
    - Patients with a rare gynecologic malignancy of the vulva including verrucous carcinoma; melanoma; aggressive angiomyxoma; sarcoma; malignant Paget's disease; or Bartholin gland carcinoma
    - Patients with a gestational trophoblastic tumor
    - Patients with a tumor arising in endometriosis
  - Group C: Women who underwent prophylactic oophorectomy and have at least 1 gram of ovarian tissue and blood available for submission for this protocol
  - Group D: Women who underwent surgery to monitor or treat a persistent or recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent tumor, normal tissue, and blood available for submission for this protocol
Concurrent primary cancers are allowed
No benign cystic tumors of the ovary, including cystic epithelial tumors and mature cystic teratomas

PATIENT CHARACTERISTICS: Not specified

PRIOR CONCURRENT THERAPY:

Chemotherapy:

Prior cytotoxic chemotherapy allowed

Endocrine therapy:

Prior hormonal therapy allowed

Radiotherapy:

Prior radiotherapy allowed

Surgery:

Prior surgery allowed
No more than 6 weeks after prior surgery

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00897442

Show 125 Study Locations

Sponsors and Collaborators

Gynecologic Oncology Group

National Cancer Institute (NCI)

Investigators

Study Chair:

Michael L. Cibull, MD

Lucille P. Markey Cancer Center at University of Kentucky

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Jewell EL, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Secord AA. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Sep 18; [Epub ahead of print]

He X, Pool M, Darcy KM, Lim SB, Auersperg N, Coon JS, Beck WT. Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene. 2007 Jul 26;26(34):4961-8. Epub 2007 Feb 19.

Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A; Gynecologic Oncology Group study. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):221-32. Epub 2007 May 3.

Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2007 Aug;106(2):325-33. Epub 2007 May 25.

Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:166-71.

Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006 Jan 15;66(2):1181-90.

Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother. 2004 May-Jun;27(3):211-9.

Depasquale S, Lambert-Messerlian G, Quddus MR, Campbell I, Steinhoff M, Gajewski W, Granai C, Tantravahi U. Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. Int J Gynecol Cancer. 2002 Sep-Oct;12(5):443-7.

Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 2006 Feb 1;66(3):1354-62.

Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006 Mar 30;25(14):2060-9.

Shi W, Hemminki A, Bartlett JS. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol. 2006 Dec;103(3):1054-62. Epub 2006 Jul 25.

Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci J 3rd, Monk BJ, Moore DH; Gynecologic Oncology Group. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Dec;103(3):853-8. Epub 2006 Jul 3.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J. 2005 Jan 12;24(1):73-84. Epub 2004 Dec 9.

Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N; Gynecologic Oncology Group. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar;96(3):810-7.

Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7.

Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005 Nov;5(17):4589-96.

Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005 Mar 15;338(2):284-93.

Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005 Aug 1;11(15):5539-48.

Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res. 2005 Mar 15;11(6):2123-31.

Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, Hanash S. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics. 2005 Feb 10;6:26.

Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005 Jun;159(2):114-22.

Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 2004 Nov;191(5):1552-72. Review.

Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol. 2004 Oct;95(1):62-9.

Berry NB, Cho YM, Harrington MA, Williams SD, Foley J, Nephew KP. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol. 2004 Mar;92(3):896-904.

Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. 2004 Jul 1;101(1):106-15.

Havrilesky LJ, Alvarez AA, Whitaker R, et al.: Loss of expression of the P16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking P53 mutations. [Abstract] Society of Gynecologic Oncologists 2004 Annual Meeting on Women's Cancer, 7-11 February 2004, San Diego, California. A-814, 2004.

He X, Ee PL, Coon JS, Beck WT. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res. 2004 Jul 15;10(14):4652-60.

Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 2004 Jan 15;10(2):681-90.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

Cvetkovi? D, Williams SJ, Hamilton TC. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin Cancer Res. 2003 Mar;9(3):1013-20.

Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE, Birrer MJ; Gynecologic Oncology Group. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003 Mar 15;63(6):1235-41.

Freitas S, Moore DH, Michael H, Kelley MR. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res. 2003 Oct 15;9(13):4689-94.

Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A; Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003 Oct 15;21(20):3814-25.

Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res. 2003 Jan;9(1):44-51.

Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8. Epub 2003 Oct 1.

Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, West JA, Rostan S, Nguyen KC, Powers S, Ye KQ, Olshen A, Venkatraman E, Norton L, Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 2003 Oct;13(10):2291-305. Epub 2003 Sep 15.

Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A, Peng Y, Pei L, Marks JR, Lowe S, Hoey T, Jan LY, McCombie WR, Wigler MH, Powers S. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 2003 Mar;3(3):297-302.

Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003 Feb 20;190(2):125-33. Review.

Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF 3rd, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003 Sep 1;63(17):5243-50.

Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003 Jul;9(7):2567-75.

Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene. 2003 Oct 16;22(46):7225-32.

Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 2003 Nov 1;9(14):5299-305.

Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res. 2003 Jun 1;63(11):2913-22.

Shedden KA, Taylor JM, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR, Gruber SB, Logsdon C, Simeone D, Kardia SL, Greenson JK, Cho KR, Beer DG, Fearon ER, Hanash S. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol. 2003 Nov;163(5):1985-95.

Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003 May 1;63(9):2164-71.

Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 2003 Apr;7(4):515-25.

Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res. 2003 Jun;9(6):2277-87.

Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard JM, Kuick R, Hanash S, Schwartz DR, Fearon ER, Cho KR. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol. 2003 May;162(5):1603-10.

Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res. 2003 Jan;9(1):264-72.

Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res. 2003 Jul 15;63(14):4225-31.

Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, Fearon ER. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 2002 Mar;1(2):145-55.

Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002 Jun 14;277(24):21657-65. Epub 2002 Apr 8.

Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247-58. Review.

Okamoto A, Woodworth CD, Yen K, Chung J, Isonishi S, Nikaido T, Kiyokawa T, Seo H, Kitahara Y, Ochiai K, Tanaka T. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol Rep. 1999 Mar-Apr;6(2):269-76.

Perlman EJ, Hu J, Ho D, Cushing B, Lauer S, Castleberry RP. Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization. J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):100-5.

Reedy M, Gallion H, Fowler JM, Kryscio R, Smith SA. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2002 May;85(2):255-9.

Roberts D, Williams SJ, Cvetkovic D, Weinstein JK, Godwin AK, Johnson SW, Hamilton TC. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol. 2002 Jan;21(1):11-9.

Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res. 2002 May 15;62(10):2923-8.

Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002 Aug 15;62(16):4722-9.

Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 2002 Sep 1;16(17):2252-63.

Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002 Jul 18;21(31):4863-71.

Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 2002 Jul;8(7):2246-52.

Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, Nieman MT, Fearon ER, Cho KR. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol. 2002 Apr;160(4):1229-38.

Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, Nephew KP. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol. 2001 Aug;82(2):261-8.

Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, Misek DE, Greenson JK, Kardia SL, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, Hanash S. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001 Oct;159(4):1231-8.

Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001 May;75(9):4283-96.

Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther. 2001 Sep 20;12(14):1697-711.

Smith SA, Richards WE, Caito K, Hanjani P, Markman M, DeGeest K, Gallion HH. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol. 2001 Dec;83(3):586-92.

Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81.

Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001 Nov 15;61(22):8247-55.

Best CJ, Gillespie JW, Englert CR, Swalwell JI, Pfeifer J, Krizman DB, Petricoin EF, Liotta LA, Emmert-Buck MR. New approaches to molecular profiling of tissue samples. Anal Cell Pathol. 2000;20(1):1-6. Review. No abstract available.

Blumenthal RD, Samoszuk M, Taylor AP, Brown G, Alisauskas R, Goldenberg DM. Degranulating eosinophils in human endometriosis. Am J Pathol. 2000 May;156(5):1581-8.

Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, Bostwick DG, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prange C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH. Molecular profiling of clinical tissue specimens: feasibility and applications. Am J Pathol. 2000 Apr;156(4):1109-15. Review. No abstract available.

Gaiotti D, Chung J, Iglesias M, Nees M, Baker PD, Evans CH, Woodworth CD. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog. 2000 Feb;27(2):97-109.

Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J, Moss P, Paeper B, Wang K. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene. 2000 Oct 17;257(1):119-30.

Hu JF, Ulaner GA, Oruganti H, Ivaturi RD, Balagura KA, Pham J, Vu TH, Hoffman AR. Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens. Biochim Biophys Acta. 2000 Apr 25;1491(1-3):49-56.

Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, Woodworth CD. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res. 2000 Aug 1;60(15):4289-98.

Ross JA, Radloff GA, Davies SM. H19 and IGF-2 allele-specific expression in hepatoblastoma. Br J Cancer. 2000 Feb;82(4):753-6.

Strausberg RL, Buetow KH, Emmert-Buck MR, Klausner RD. The cancer genome anatomy project: building an annotated gene index. Trends Genet. 2000 Mar;16(3):103-6. No abstract available.

Underwood LJ, Shigemasa K, Tanimoto H, Beard JB, Schneider EN, Wang Y, Parmley TH, O'Brien TJ. Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta. 2000 Nov 15;1502(3):337-50.

Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR, Kohn EC. Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Gynecol Oncol. 1999 Jul;74(1):98-102. Review.

Hanna EA, Umhauer S, Roshong SL, Piechocki MP, Fernstrom MJ, Fanning JD, Ruch RJ. Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro. Carcinogenesis. 1999 Jul;20(7):1369-73.

Krizman DB, Wagner L, Lash A, Strausberg RL, Emmert-Buck MR. The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression. Neoplasia. 1999 Jun;1(2):101-6. Review.

Ross JA, Schmidt PT, Perentesis JP, Davies SM. Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. Cancer. 1999 Mar 15;85(6):1389-94.

Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 1999 Sep 1;59(17):4435-9.

Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999 Mar 18;229(1-2):101-8.

Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):775-82.

DiPaolo JA, Woodworth CD, Coutlée F, Zimonic DB, Bryant J, Kessous A. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer. 1998 Jun 10;76(6):865-71.

Malins DC, Polissar NL, Schaefer S, Su Y, Vinson M. A unified theory of carcinogenesis based on order-disorder transitions in DNA structure as studied in the human ovary and breast. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7637-42.

Peterson LA, Brown MR, Carlisle AJ, Kohn EC, Liotta LA, Emmert-Buck MR, Krizman DB. An improved method for construction of directionally cloned cDNA libraries from microdissected cells. Cancer Res. 1998 Dec 1;58(23):5326-8.

Rakowicz-Szulczynska EM, Jackson B, Snyder W. Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. Cancer Lett. 1998 Feb 27;124(2):213-23.

Riopel MA, Spellerberg A, Griffin CA, Perlman EJ. Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res. 1998 Jul 15;58(14):3105-10.

Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998 Apr;178(4):670-7.

Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res. 1997 Feb 1;57(3):513-5.

Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997 Mar 15;99(6):1390-8.

Courtois SJ, Woodworth CD, Degreef H, Garmyn M. Early ultraviolet B-induced G1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. Exp Cell Res. 1997 May 25;233(1):135-44.

Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997 Aug;66(2):250-4.

Ilekis JV, Gariti J, Niederberger C, Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol. 1997 Apr;65(1):36-41.

Lei XD, Woodworth CD, Johnen G, Kaufman S. Expression of 4alpha-carbinolamine dehydratase in human epidermal keratinocytes. Biochem Biophys Res Commun. 1997 Sep 18;238(2):556-9.

Schweinfest CW, Graber MW, Chapman JM, Papas TS, Baron PL, Watson DK. CaSm: an Sm-like protein that contributes to the transformed state in cancer cells. Cancer Res. 1997 Jul 15;57(14):2961-5.

DiPaolo JA, Popescu NC, Woodworth CD, Zimonjic DB. Papillomaviruses and potential copathogens. Toxicol Lett. 1996 Nov;88(1-3):1-7. Review.

Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol. 1996;17(6):487-92.

Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet. 1996 Mar;12(3):298-302. Erratum in: Nat Genet 1998 May;19(1):102.

Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT. BRCA1 is secreted and exhibits properties of a granin. Nat Genet. 1996 Mar;12(3):303-8.

Kremer R, Woodworth CD, Goltzman D. Expression and action of parathyroid hormone-related peptide in human cervical epithelial cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C164-71.

Lancaster JM, Cochran CJ, Brownlee HA, Evans AC, Berchuck A, Futreal PA, Wiseman RW. Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. J Natl Cancer Inst. 1996 Apr 17;88(8):552-4. No abstract available.

Phillips NJ, Zeigler MR, Deaven LL. A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett. 1996 Apr 19;102(1-2):85-90.

Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996 Nov 7;335(19):1413-6.

Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res. 1996 May 1;56(9):1997-2002.

Scoccia B, Lee YM, Niederberger C, Ilekis JV. Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Investig. 1998 May-Jun;5(3):161-5.

Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O'Brien TJ. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig. 1999 Mar-Apr;6(2):102-8.

Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet. 1998 Feb;7(2):195-202.

Simpson S, Woodworth CD, DiPaolo JA. Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene. 1997 May 8;14(18):2149-57.

Tanimoto H, Mehta KD, Parmley TH, Shigemasa K, Parham GP, Clarke J, O'Brien TJ. Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation. Gynecol Oncol. 1997 Aug;66(2):308-12.

Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997 Jul 15;57(14):2884-7.

Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 1996 Dec 5;384(6608):470-4.

Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 1996 Apr 15;56(8):1761-5.

Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, Cardonick A, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC, Boyd J. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996 Jun 15;56(12):2738-41.

Tripathi PK, Chatterjee SK. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest. 1996;14(6):518-26.

Woodworth CD, Chung J, McMullin E, Plowman GD, Simpson S, Iglesias M. Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation. Cell Growth Differ. 1996 Jun;7(6):811-20.

Alvarez-Salas LM, Velazquez A, Lopez-Bayghen E, Woodworth CD, Garrido E, Gariglio P, DiPaolo JA. Transcriptional repression in normal human keratinocytes by wild-type and mutant p53. Cancer Lett. 1995 May 4;91(1):85-92.

Bukovsky A, Caudle MR, Keenan JA, Wimalasena J, Foster JS, Upadhyaya NB, van Meter SE. Expression of cell cycle regulatory proteins (p53, pRb) in the human female genital tract. J Assist Reprod Genet. 1995 Feb;12(2):123-31.

Bukovský A, Caudle MR, Keenan JA, Wimalasena J, Foster JS, Van Meter SE. Quantitative evaluation of the cell cycle-related retinoblastoma protein and localization of Thy-1 differentiation protein and macrophages during follicular development and atresia, and in human corpora lutea. Biol Reprod. 1995 Apr;52(4):776-92.

Bukovský A, Caudle MR, Keenan JA, Wimalasena J, Upadhyaya NB, Van Meter SE. Is corpus luteum regression an immune-mediated event? Localization of immune system components and luteinizing hormone receptor in human corpora lutea. Biol Reprod. 1995 Dec;53(6):1373-84.

Bukovský A, Keenan JA, Caudle MR, Wimalasena J, Upadhyaya NB, Van Meter SE. Immunohistochemical studies of the adult human ovary: possible contribution of immune and epithelial factors to folliculogenesis. Am J Reprod Immunol. 1995 Apr;33(4):323-40.

Cameron MR, Caudle MR, Sullivan WR Jr, Peluso JJ, Wimalasena J. The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Oncol Res. 1995;7(3-4):145-56.

Gallion HH, Pieretti M, DePriest PD, van Nagell JR Jr. The molecular basis of ovarian cancer. Cancer. 1995 Nov 15;76(10 Suppl):1992-7. Review.

Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32.

Gordon AW, Pegues JC, Johnson GR, Kannan B, Auersperg N, Stromberg K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett. 1995 Feb 10;89(1):63-71.

Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol. 1995 Apr;146(4):944-52.

Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer. 1995 Dec 20;64(6):434-40.

Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol. 1995 Apr;26(4):393-7.

Pieretti M, Powell DE, Gallion HH, Conway PS, Case EA, Turker MS. Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum Pathol. 1995 Apr;26(4):398-401.

Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 1995 May 15;55(10):2150-7.

Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995 Jul 15;55(14):2998-3002.

Woodworth CD, McMullin E, Iglesias M, Plowman GD. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2840-4.

Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22;264(5158):569-71.

Harris JD, Hibler DW, Fontenot GK, Hsu KT, Yurewicz EC, Sacco AG. Cloning and characterization of zona pellucida genes and cDNAs from a variety of mammalian species: the ZPA, ZPB and ZPC gene families. DNA Seq. 1994;4(6):361-93.

Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994 Jun 1;54(11):2837-40.

Orth K, Hung J, Gazdar A, Bowcock A, Mathis JM, Sambrook J. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9495-9.

Orth K, Hung J, Gazdar A, Mathis M, Bowcock A, Sambrook J. Ovarian tumors display persistent microsatellite instability caused by mutation in the mismatch repair gene hMSH-2. Cold Spring Harb Symp Quant Biol. 1994;59:349-56. No abstract available.

Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994 May 1;73(9):2432-43.

Rowell S, Newman B, Boyd J, King MC. Inherited predisposition to breast and ovarian cancer. Am J Hum Genet. 1994 Nov;55(5):861-5. Review. No abstract available.

Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994 Feb 8;33(5):1209-15.

Stromberg K, Johnson GR, O'Connor DM, Sorensen CM, Gullick WJ, Kannan B. Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol. 1994 Oct;13(4):342-7.

Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, Clarke J, O'Brien TJ. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol. 1999 Mar-Apr;20(2):88-98.

Varricchio F, Stromberg K. An albumin-like protein is the major secretory protein of ovarian epithelial cells in vivo and in vitro. Int J Gynecol Cancer. 1994 Sep;4(5):328-332.

Coppes MJ, Ye Y, Rackley R, Zhao XL, Liefers GJ, Casey G, Williams BR. Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res. 1993 Jun 15;53(12):2712-4.

Woodworth CD, Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol. 1993 May;142(5):1544-55.

Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, Notario V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ. 1993 May;4(5):367-76.

ClinicalTrials.gov Identifier:	NCT00897442 History of Changes
Other Study ID Numbers:	CDR0000078647, GOG-0136
Study First Received:	May 9, 2009
Last Updated:	December 3, 2011
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

childhood malignant ovarian germ cell tumor
ovarian serous cystadenocarcinoma
ovarian serous cystadenoma with proliferating activity
recurrent ovarian germ cell tumor
recurrent ovarian epithelial cancer
stage IV ovarian epithelial cancer
stage III borderline ovarian surface epithelial-stromal tumor
stage IV borderline ovarian surface epithelial-stromal tumor
uterine corpus cancer
cervical adenocarcinoma
cervical adenosquamous cell carcinoma
cervical small cell carcinoma
cervical squamous cell carcinoma
recurrent cervical cancer
stage IA cervical cancer

stage IB cervical cancer
stage IIA cervical cancer
stage IIB cervical cancer
stage III cervical cancer
stage IVA cervical cancer
stage IVB cervical cancer
squamous cell carcinoma of the vulva
Brenner tumor
malignant mesothelioma
uterine leiomyosarcoma
endometrial stromal sarcoma
neoplasm of uncertain malignant potential
melanoma
embryonal childhood rhabdomyosarcoma
Paget disease of the vulva

ClinicalTrials.gov processed this record on February 09, 2012